|
1
|
Radhakrishnan V, Thampy C, Ganesan P,
Rajendranath R, Ganesan TS, Rajalekshmy KR and Sagar TG: Acute
myeloid leukemia in children: Experience from Tertiary cancer
Centre in India. Indian J Hematol Blood Transfus. 32:257–261.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kulkarni KP and Marwaha RK: Childhood
acute myeloid leukemia: An Indian perspective. Pediatr Hematol
Oncol. 28:257–268. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kavcic M, Fisher BT, Li Y, Seif AE, Torp
K, Walker DM, Huang YS, Lee GE, Tasian SK, Vujkovic M, et al:
Induction mortality and resource utilization in children treated
for acute myeloid leukemia at free-standing pediatric hospitals in
the United States. Cancer. 119:1916–1923. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Taga T, Tomizawa D, Takahashi H and Adachi
S: Acute myeloid leukemia in children: Current status and future
directions. Pediatr Int. 58:71–80. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tomizawa D, Tabuchi K, Kinoshita A, Hanada
R, Kigasawa H, Tsukimoto I and Tsuchida M: Tokyo Children's Cancer
Study Group. Repetitive cycles of high-dose cytarabine are
effective for childhood acute myeloid leukemia: Long-term outcome
of the children with AML treated on two consecutive trials of Tokyo
Children's Cancer Study Group. Pediatr Blood Cancer. 49:127–132.
2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Okamoto Y, Kudo K, Tabuchi K, Tomizawa D,
Taga T, Goto H, Yabe H, Nakazawa Y, Koh K, Ikegame K, et al:
Hematopoietic stem-cell transplantation in children with refractory
acute myeloid leukemia. Bone Marrow Transplant. 54:1489–1498.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bose P, Vachhani P and Cortes JE:
Treatment of Relapsed/Refractory acute myeloid leukemia. Curr Treat
Options Oncol. 18(17)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vardiman JW, Harris NL and Brunning RD:
The World Health Organization (WHO) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Thol F, Schlenk RF, Heuser M and Ganser A:
How I treat refractory and early relapsed acute myeloid leukemia.
Blood. 126:319–327. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bezwoda WR and Dansey RD: Idarubicin plus
Cytarabine versus doxorubicin plus cytarabine in induction therapy
for acute non-lymphoid leukaemia: A randomized trial. Leuk
Lymphoma. 1:221–225. 1990.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sander A, Zimmermann M, Dworzak M,
Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJ and Creutzig
U: Consequent and intensified relapse therapy improved survival in
pediatric AML: Results of relapse treatment in 379 patients of
three consecutive AML-BFM trials. Leukemia. 24:1422–1428.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen F, Wang J, Hou M, Zhao H, Yang E, Ran
X, Wang M, Yu W, Xu R, Wang Z, et al: Prospective multicentre study
of chemotherapeutic regimen containing pirarubicin on the treatment
of relapsed or refractory acute myeloid leukemia in adults.
Zhonghua Xue Ye Xue Za Zhi. 35:388–392. 2014.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
13
|
Liedtke M, Dunn T, Dinner S, Coutré SE,
Berube C, Gotlib J, Patel S and Medeiros B: Salvage therapy with
mitoxantrone, etoposide and cytarabine in relapsed or refractory
acute lymphoblastic leukemia. Leuk Res. 38:1441–1445.
2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jackson G, Taylor P, Smith GM, Marcus R,
Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB,
et al: Amulticentre, open, Non comparative phase II study of a
combination of fludarabine phosphate, cytarabine and granulocyte
colony-stimulating factor in relapsed and refractory acute myeloid
leukemia and de novo refractory anemia with excess of blasts in
transformation. Br J Hematol. 112:127–137. 2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zeidner JF, Vincent BG, Esparza S, Ivanova
A, Moore DT, Foster MC, Coombs CC, Jamieson K, Van Deventer HW,
Blanchard L, et al: Final clinical results of a phase II study of
high dose cytarabine followed by pembrolizumab in
relapsed/refractory AML. Blood. 134 (Suppl 1)(S831)2019.
|
|
16
|
Pastore D, Specchia G, Carluccio P, Liso
A, Mestice A, Rizzi R, Greco G, Buquicchio C and Liso V: FLAG-IDA
in the treatment of refractory/relapsed acute myeloid leukemia:
Single-center experience. Ann Hematol. 82:231–235. 2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ruan M, Liu LP, Zhang AL, Quan Qi B, Liu
F, Liu TF, Liu XM, Chen XJ, Yang WY, Guo Y, et al: Improved outcome
of children with relapsed/refractory acute myeloid leukemia by
addition of cladribine to re-induction chemotherapy. Cancer Med.
10:956–964. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Luskin MR, Lee JW, Fernandez HF,
Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL,
Litzow MR, Paietta EM, et al: Benefit of high-dose daunorubicin in
AML induction extends across cytogenetic and molecular groups.
Blood. 127:1551–1558. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bozoglan H, Ergene U and Yoleri L: Use of
cytarabine and idarubicin in a newly diagnosed AML patient with a
severe wound. Transfus Apher Sci. 45:17–20. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ziogas DC, Voulgarelis M and Zintzaras E:
A Network Meta-analysis of randomized controlled trials of
induction treatments in acute myeloid leukemia in the elderly. Clin
Ther. 33:254–279. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mandelli F, Vignetti M, Suciu S, Stasi R,
Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, et al:
Daunorubicin versus mitoxantrone versus idarubicin as induction and
consolidation chemotherapy for adults with acute myeloid leukemia:
The EORTC and GIMEMA Groups Study AML-10. J Clin Oncol.
27:5397–5403. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Murphy T and Yee KWL: Cytarabine and
daunorubicin for the treatment of acute myeloid leukemia. Expert
Opin Pharmacother. 18:1765–1780. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fenaux P, Mufti GJ, Hellström-Lindberg E,
Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S,
Seymour JF, et al: Azacitidine prolongs overall survival compared
with conventional care regimens in elderly patients with low bone
marrow blast count acute myeloid leukemia. J Clin Oncol.
28:562–569. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lübbert M, Rüter BH, Claus R, Schmoor C,
Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker
U, et al: A multicenter phase II trial of decitabine as first-line
treatment for older patients with acute myeloid leukemia judged
unfit for induction chemotherapy. Hematologica. 97:393–401.
2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ritchie EK, Feldman EJ, Christos PJ, Rohan
SD, Lagassa CB, Ippoliti C, Scandura JM, Carlson K and Roboz GJ:
Decitabine in patients with newly diagnosed and relapsed acute
myeloid leukemia. Leuk Lymphoma. 54:2003–2007. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tawfik B, Sliesoraitis S, Lyerly S, Klepin
HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D,
et al: Efficacy of the hypomethylating agents as frontline,
salvage, or consolidation therapy in adults with acute myeloid
leukemia (AML). Ann Hematol. 93:47–55. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Herman JG and BayIin SB: Gene silencing in
cancer in association with promoter hyper methylation. N Engl J
Med. 349:2042–2054. 2003.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Qin T, Youssef EM, Jelinek J, Chen R, Yang
AS, Garcia-Manero G and Issa JP: Effect of cytarabine and
decitabine in combination in human leukemic cell lines. Clin Cancer
Res. 13:4225–4232. 2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Huang MT: Harringtonine, an inhibitor of
initiation of protein biosynthesis. Mol Pharmacol. 11:511–519.
1975.PubMed/NCBI
|
|
30
|
Zhou DC, Zittoun R and Marie JP:
Homoharringtonine: An effective new natural product in cancer
chemotherapy. Bull Cancer. 82:987–995. 1995.PubMed/NCBI
|
|
31
|
Bose P, Verstovsek S, Gasior Y, Jain N,
Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau
SM, et al: Phase I/II study of Ruxolitinib (RUX) with decitabine
(DAC) in patients with post-myeloproliferative neoplasm acute
myeloid leukemia (post-MPN AML): Phase I results. Blood.
128(4262)2016.
|
|
32
|
Zhu HH, Jiang H, Jiang Q, Jia JS, Qin YZ
and Huang XJ: Homoharringtonine, aclarubicin and cytarabine (HAA)
regimen as the first course of induction therapy is highly
effective for acute myeloid leukemia with t(8;21). Leuk Res.
44:40–44. 2016.PubMed/NCBI View Article : Google Scholar
|
